CalmiGo

Deep Longevity and Longenesis collaborate to clock aging

Latest articles

Billionaire donates $220m for peak performance research

Salk Institute, UC San Diego and Stanford given $220 million by Wu Tsai Human Performance Alliance to research molecular underpinnings of peak human performance. A Salk...

Longevity senotherapeutics report: Insilico Medicine

Insilico – on a mission to accelerate senescence drug discovery and development by continuously inventing and deploying new AI technologies. Over the coming weeks, we...

Product review: Bearaby weighted blanket

Bearaby weighted blankets are on a mission to provide you with deep sleep, peace of mind and a joyful feeling.   GO LONG    GO SHORT ...

Aging well: the new human imperative

Prof Andrew Scott touts the importance of compressing morbidity and aging well to realise multi-trillion dollar benefit of increasing life expectancy. Earlier this year, we...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...
Seno

Editor's picks

Billionaire donates $220m for peak performance research

Salk Institute, UC San Diego and Stanford given $220 million by Wu Tsai Human Performance Alliance to research molecular underpinnings of peak human performance. A Salk...

Longevity senotherapeutics report: Insilico Medicine

Insilico – on a mission to accelerate senescence drug discovery and development by continuously inventing and deploying new AI technologies. Over the coming weeks, we...

Product review: Bearaby weighted blanket

Bearaby weighted blankets are on a mission to provide you with deep sleep, peace of mind and a joyful feeling.   GO LONG    GO SHORT ...
CalmiGo

Click the globe for translations.

Start the clock to stop the clock – centralised data will aid Longevity research. 

Deep Longevity, which engages in the development of explainable AI systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological and psychological levels, has entered into a partnership with Longenesis, a company focused on consent-enabled safe data curation for research.

Longevity.Technology: Aging clocks are big news. From skin age to DNA methylation, advances in AI, combined with ever-growing datasets, have led to an explosion in the field. Not only do aging clocks increase the variety of biomarkers that could predict biological age, but they speed identification of novel therapeutic targets. In addition, deep aging clocks can be used for data quality control and evaluation of the biological relevance and value of various data types and combinations. 

This collaboration will integrate Longenesis’ consent management system developed by Longenesis into the Deep Longevity digital platform (which already includes Young.AI, a web-based tracker of aging and wellness). The companies will also be developing a federated learning framework together.

“At Deep Longevity we are working on creating a network of hospitals and clinics that will have access to our aging clocks. To enable this network, we are aiming to create a federated learning pipeline, that will allow us to train multiple new aging clocks without the need to transfer user data,” explains Polina Mamoshina, PhD, Chief Scientific Officer of Deep Longevity, a Regent Pacific company.

Longenesis graphic showing data sharing. Source: Longenesis

“Longenesis is a company invested by LongeVC, a venture fund, and accelerator dedicated to growing the longevity ecosystem in the European Union,” says Garry Zmudze, founding partner of LongeVC, an investor in both Longenesis and Deep Longevity. “Over the past few years, Longenesis developed a range of technologies to help protect user privacy and manage consent to help companies provide the individuals with more tools to take control over their data.”

 


 

 

“At Longenesis we believe that the need for centralized, compliant and seamless biomedical data asset identification is crucial for collaborative research initiation, faster patient recruitment and timely response to global healthcare challenges,”

 


 

“At Longenesis we believe that the need for centralized, compliant and seamless biomedical data asset identification is crucial for collaborative research initiation, faster patient recruitment and timely response to global healthcare challenges,” comments Sergejs Jakimovs, a CEO of Longenesis. “We are looking forward to this collaboration, creating a federated learning pipeline and embracing the “data stays local” principle at the same time.”

As the number of clocks and data extrapolated from them grows, having ready access available to hospitals, clinicians and researchers could prove invaluable in the fight against aging, as well as helping to combat age-related diseases. At Longevity.Technology we feel there is a need for a common standard for data management of client/patient data in the Longevity field. It’s a win/win as easier onboarding (one form for multiple biomarkers, one portal to manage results and plan interventions, &c), means more people are likely to start using aging clock technology themselves.

Image credit: By helloabc / Shutterstock

1 COMMENT

  1. […] Deep Longevity has entered into a partnership with Longenesis; this collaboration will integrate Longenesis’ consent management system into the Deep Longevity digital platform (which already includes Young.AI, a web-based tracker of ageing and wellness). The companies will also be developing a federated learning framework together.  […]

Comments are closed.

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
CalmiGo

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...
Seno

Related articles

Longevity senotherapeutics report: Insilico Medicine

Insilico – on a mission to accelerate senescence drug discovery and development by continuously inventing and deploying new AI technologies. Over the coming weeks, we...

Targeting senescence improves kidney regenerative functions

A new study finds that the administration of a compound selectively toxic to senescent cells, can improve functional renal recovery, reduce fibrosis and increase...

US Special Ops will test antiaging pill

From delaying the onset of aging, to improving recovery time, the US military has its sights set on the age of marvel. From duct tape...

Longevity senotherapeutics report: Cleara Biotech

Cleara Biotech – on a mission to target cellular senescence to extend human healthspan at old age. Over the coming weeks, we will be bringing...

Campisi Lab to partner with pharma firm on senescence

Buck professor talks about taking the right approach to senescence, key indications, and forthcoming research and collaborations from her lab. In our first article with...
Seno